Download pdf - Drug Discovery 2012 - ELRIG · Innovation Initiative. Chris received a B.S. in Biology from Cornell University and a Ph.D in Molecular and Cellular Pharmacology from the State University

www.elrig.org

Drug Discovery 2012Manchester Central Convention Complex, UK

5th & 6th September 2012

In collaboration with

Welcome WordsWelcome to the sixth Drug Discovery meeting organized by ELRIG(European Laboratory Robotics Interest Group) in collaboration withSLAS (Society for Laboratory Automation and Screening).

Proposals for the annual ELRIG Drug Discovery meeting weredeveloped during 2005 and 2006 and led to the first meeting beingheld in Nottingham in 2007. Since that time we have had the privilegeof acting as program chairs for six annual meetings. We have seen themeeting double in size, have established the leading vendor exhibitionin the UK and have welcomed many eminent scientists includingJamie Thomson, Chris Lipinski and Philip Cohen to the meeting. Moreimportantly, the Drug Discovery meeting has become establishedwithin the meetings calendar as the major meeting place in the UK forscientists from pharma, biotech and academia interested in thechallenges of pre-candidate drug discovery.

We would now like to welcome delegates, exhibitors and speakersto the sixth annual meeting to be held once again at the ManchesterCentral exhibition centre. This meeting marks our final year as programchairs. Over the next two days a superb range of world-class Speakerswill be presenting in eight sessions covering a wide range of topicalissues for Drug Discovery including advances in Fragment Based DrugDiscovery and the complimentary biophysical and label freetechnologies applied in this field. We will explore the biology ofepigenetic enzymes and ubiquitinases as two novel families of drugtargets. We will once again discuss advances in assay developmentand screening, compound management and compound collectionenhancement, liquid handling and detection technologies. Buildingon the success of previous years we will review the application ofprimary and stem cells in discovery. In addition, the 2012 meeting willcontain two lunchtime sessions in collaboration with SLAS to explorethe growing informatics challenge of extracting knowledge fromlaboratory data.

The meeting features an extensive array of posters, snapshot talks,training, several competitions and probably the best exhibition forDrug Discovery products and services in the UK which incorporates athriving Innovation Zone for new companies promoting excitingtechnologies to the market. We also add to our conference programwhat we hope will be a challenging and entertaining Dragon’s Denevent in which innovators will present new ideas to a panel of industryleaders for discussion. Finally there will be a range of exhibitororganised meetings and training courses.

The meeting will end with a debate on the Evolving Landscape ofDrug Discovery hosted by Chris Moxham who will discuss the Lillymodel of Open Innovation and Steve Rees from AstraZeneca who willdiscuss Collaborative models for Lead Discovery.

In developing the program for this meeting ELRIG is placed at thecentre of our community with the objective of bringing togetherscientists from across the field, whether they are based in academia,the pharmaceutical or biotech industries, in order to establishrelationships to advance the science of drug discovery in the UKand Europe.

As in past years registration and attendance at the show is FREE – wecan only do this because of the support of our sponsors and exhibitors.

As we now pass the baton to Del Trezise (Essen) and Peter Simpson(AstraZeneca) the Program Chairs for the 2013 show, we would like tothank everyone who has contributed to six years of the Drug Discoveryevent but, especially Jackie Howard and Dermot Boylan of ELRIGwithout whom these meetings simply would not happen.

Drug Discovery 2013 will be back in Manchester on 3rd & 4thSeptember 2013 so please make a date in your diary!

With best regards,

Adrian Kinkaid and Stephen ReesProgram Chairs Drug Discovery 2012

About ELRIGELRIG is a Not For Profit special interest group focused on the use of automation, robotics and instrumentation in the laboratory andalso on the wider applications of laboratory automation.

Our membership consists of scientists, researchers, engineers, developers andbusiness-people who are interested in robotics, automation and associatedtechnological developments in this field.

Our primary objective is to provide an open communication forum for usersand vendors, within which members can be educated, share information andexperience and network with other members.

Our primary means of achieving this is to organise Meetings and Conferencesin which our members' experiences of automation are presented and atwhich relevant vendors exhibit their latest technology. Our aim is to provideworld-class meetings and conferences which are accessible to all.

In order to meet our open-access aims, we operate a business model in whichdelegate access to our meetings is Free of Charge. We aim to cover the cost ofstaging our events from the contributions of the exhibitors and sponsors.

About SLASThe Society for Laboratory Automation and Screening (SLAS) is aninternational community of more than 10,000 individual scientists, engineers,researchers, technologists and others from academic, government andcommercial laboratories. SLAS provides forums for education andinformation exchange to encourage the study of and advance laboratoryscience and technology for the drug discovery, agrochemical, biotechnology,chemical, clinical diagnostic, consumer product, energy, food, forensic,pharmaceutical, security and other industries.

SLAS works hard to deliver tangible educational programs and services to itsmembers. Professionals at all levels who actively invest their time and energyin their SLAS memberships often experience immeasurable returns on theirinvestments. Those who contribute as volunteers and committee membersenjoy even greater advantages.

Scientific education, practical information, professional career- building, andvaluable networking opportunities can open many doors to personal andprofessional success. Acknowledge your role in the unique field of laboratoryscience and technology. Join the only international, non-profit societydevoted exclusively to your best interests. Join SLAS today at SLAS.org.

This meeting continues to be the ideal forum for users of Flow Cytometry &Imaging Systems within drug discovery and drug development to gettogether, share expertise and innovation, discuss pitfalls, successes andfuture directions. Typical attendees will be colleagues from small-tomid-sized biotech companies, contract research organisations and globalpharmaceutical companies. The content of this free two day meeting willalso include other industrial-based themes covering the drug developmentjourney from discovery to clinical evaluation.

Chris MoxhamChris is currently an Associate VicePresident at ImClone Systems, a whollyowned subsidiary of Eli Lilly andCompany. Prior to joining ImClone, hespent 12 years at Eli Lilly and Co. in avariety of leadership roles. Most

recently he led a team that developed and launched Eli Lilly’s OpenInnovation Initiative. Chris received a B.S. in Biology from CornellUniversity and a Ph.D in Molecular and Cellular Pharmacology fromthe State University of New York at Stony Brook.

Don’t Miss the Keynote Debate:

Charter 1 at 3.45 on Day 2

The Evolving Landscape of Drug DiscoveryLilly Model of Open Innovationby Chris Moxham, Lilly

Collaborative Models for Lead Discoveryby Steve Rees, AstraZeneca

Poster Awards

Keynote Speakers

ELRIG PresentsThe SLAS Young Scientist Award

Students, graduates and post-docs are welcome to compete for the SLAS Young Scientist Award at theELRIG Drug Discovery 2012 Annual Conference and Exhibition, September 5-6, at Manchester Central, United Kingdom.

Students, graduates and post-docs are welcome to compete for the SLAS Young Scientist Award at the ELRIG Drug Discovery 2012 AnnualConference and Exhibition, September 5-6, at Manchester Central, United Kingdom.

The winner will be invited to present and participate in the Student Poster Competition at the 2nd Annual SLAS Conference and Exhibition,January 12-16, 2013 at the Gaylord Palms Resort and Convention Center in Orlando, Florida, USA. SLAS Young Scientist Award winners receive a$500 cash prize, round-trip coach airfare, shared hotel accommodations and conference registration for SLAS2013.

The winner will be invited to present and participate in the Student Poster Competition at the 2nd Annual SLAS Conference and Exhibition,January 12-16, 2013 at the Gaylord Palms Resort and Convention Center in Orlando, Florida, USA. SLAS Young Scientist Award winners receive

a $500 cash prize, roundtrip coach airfare, shared hotel accommodations and conference registration for SLAS2013.

The SLAS Young Scientist Award program is a global initiative in partnership with the following organizations:• European Laboratory Robotics Interest Group, United Kingdom• Institute of Food Technologists, United States• MipTec, Switzerland• International Society for Stem Cell Research, United States

For information regarding the ELRIG Drug Discovery 2012 SLAS Young Scientist Award,please contact Dermot Boylan, ELRIG Executive Director, at [email protected].

Steve ReesSteve Rees is Vice-President of ScreeningSciences and Sample Management atAstraZeneca with global responsibilityfor High Throughput Screening,Compound Management, the humantissue BioBank and the provision of SARbiology support to preclinical discovery

projects. Prior to joining AstraZeneca, Steve worked atGlaxoSmithKline for 24 years in various roles including that of Directorof the Screening and Compound Profiling Department. Steve hasbeen responsible for developing hit identification, compoundprofiling and compound management strategies for AstraZenencaand previously GlaxoSmithKline. Steve has led multiple internationalcollaborations and has sponsored the development andimplementation of a range of cellular assay technologies for ionchannel, GPCR and other target classes.

Steve has authored >50 scientific papers and has spoken at manyinternational symposia. Steve has been active within the Society ofLaboratory Automation and Screening (SLAS) since 2004 havingserved four years as chair of the conference committee and as a BoardMember. He is a member of the BBSRC panel of experts and is theprogram co-chair for the annual ELRIG Drug Discovery meeting.

VP Screening Sciences and Sample Management, Discovery Sciences,AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG

Lunchtime SeminarInformatics: Making Knowledge from Laboratory Data

Informatics Seminar In collaboration with SLAS- Joe Bradley, Burkhard Schaefer and Bryn Williams

Day 1 – How best to enable Externalisation of Drug DiscoveryThe last few years have seen an increasing trend to outsource screening, initially chemistry and selected

assays but increasingly entire integrated hit to lead programs with entire research areas being “virtualised”.This poses several challenges to “traditional” Pharma screening IT environments which were often not

designed to allow and coordinate inter-company screening activities.

At this session we will hear from industry experts on strategies to enable and supportthis changing landscape. This session will be an interactive, part presentation, part debate

and part open discussion on how best to achieve this.

Nick Lynch – AstraZeneca and Pistoia AllianceAnthony Carlo – Integrated Sourcing Lead, PfizerDavid Cronk – Senior Director, Biology, BioFocus

Day 2 – Knowledge at your finger tipsAt today’s session you will hear about cutting edge, open tools for use by scientists to share, find and create

information and knowledge. In order to effectively locate, interpret, link and cross reference results,information needs to be stored in a rich, standardised, computer friendly formats – these are often human

unfriendly to create and use. Now innovative, opensource tools and standards are emerging which hold thepromise to deliver these advantages in scientist friendly applications.

OpenPhacts – Dr Stefan Renner, Novartis

OpenISA – Dr Alejandra Gonzalez-Beltran , University of Oxford eResearch Centre“Community-standards for reproducible and reusable research: fundamentals and challenges”

Please note: - This informatics session is designed to be of interest and easy to follow by drug discoveryscientists of all disciplines. Talks are geared towards showing practical solutions rather than technical details.

Career Zone

Jobs Vacancies will be displayed on the Jobs Board located in the Careers Zone in the Charter Foyer – take a look.Take the opportunity of talking to the experts and get valuable Careers Advice.

If you are looking for a job, or looking for people, where better than ELRIG to network?

George James LtdGeorge James Ltd are delighted to be supporting the ELRIG DrugDiscovery Conference which has established itself as the leading

conference covering this subject hosted in the UK. During theconference we will have specialists available to provide free

45 minute advice sessions to exhibitors and delegates.

Langton HowarthLangton Howarth is a specialist recruitment consultancy working

within the Life Science, Diagnostic, Healthcare and ConsumerHealth and Beauty industries. We offer an unparalleled quality of

service and a consistent commitment towards our clients andcandidate, and aim for nothing short of excellence. Visit us at the

Careers Zone for unbiased advice about your future career move or current recruiting needs.

Visit the Vendor Lunchtime Workshops in Central 5See what others don’t – with GE Healthcare Drug Discovery Suite.

Deeper insights – better prediction of drug safety and efficacy.

Drug Discovery Suite is our portfolio of specialist technologies that allows you to achieve deeper insights atevery stage of discovery; from target identification to lead optimization. The insights into mechanisms on the

molecular as well as cellular level will help you make early predictions of drug safety and efficacyrequired to rank and select the most promising candidates to take forward.

We welcome you to our Drug Discovery Suite Seminars on the following topics:

Wednesday 5th September13.00pm – 13.40pm

Bringing Toxicology Screening into the 21st CenturyThe Power of Advanced Cell Models and High Content Analysis.

Nick Thomas, Principal Scientist, GE Healthcare Cell Technologies.

13.45pm – 14.15pmAn Innovation in Cell Analysis has Arrived – Introducing the New CytellTM Image Cytometer

Ray Ismail, Senior Scientist, GE Healthcare Cell Technologies.

Contact: Kelly Newvell on +44 (0)1622 624239 at [email protected]

Cambridge Bioscienceare sponsoring the Wi-Fithroughout the show.

The Code and Log on details are:Select: MCCC

Password: ELRIGDD12

ELRIG 2012DRAGONS DEN Join us in the Exhibition Hall at 6.30

on Day 1 where you will witness ELRIG’sanswer to DRAGONS DEN...

DragonsChris Lipinski, Pharma

Stuart Naylor, ELRIGPenny Attridge, Spark Ventures

Graeme Daniels, Cytocentrics Bioscience GmbH

Compere:Terry Wood, ELRIG Chairman

Contestants:5 Companies from within our Industry present

their New Ideas to our Panel of Dragons

Mobile App Info:Event Info in your pocket...Download the complete Drug Discovery 2012Conference schedule to your mobile device.

• View lecture and speaker profiles• View exhibitor video presentations• Rate lectures• Exhibitor interactive floor plan• In-messaging to speakers and exhibitors• Organise your day with favourites list• Share your profile as vCard and QRCode• Keep notes about lectures, speakers and exhibitors• Conference info available all year round

> For APPLE devices download at the appstore,search for EVENTFLO

> For mobile devices other than iphone and ipadplease view our 'WEBAPP' version >http://www.myeventflo.com/eventflo/eventflo.asp?pg=2&evID=1287

7 Sept 2012 in ManchesterThis half-day workshop after theELRIG conference is designed to bring scientistsworking in drug discovery and toxicology fully up todate on this hot topic. Request a 50% discountvoucher at InSphero’s stand G3 at Drug Discovery2012! Find preliminary program andregistration form here: www.insphero.com

InSpheroWorkshop“Early drug de-riskingwith 3D-cell-culturesystems”

Speaker ProgrammeSession 1, Day 1

Manchester Central Convention Complex, UK5th & 6th Sept 2012

9.00 – 9.059.05 – 9.15

Introductions andWelcomeUli Schopfer, NovartisCatherine Kettleborough, MRC

9.15 – 10.00 Session KeynoteChris Lipinski, Massachusetts University

Biologically active chemistry space and the limitsof druggability

10.00 – 10.30 Alan Harvey, Strathclyde University

Benefiting from screening natural products

10.30 – 11.00 COFFEE/ExHIBITION

11.00 – 11.30 Matthias Rottmann, Tropical Institute

Taking “one step backwards” to accelerate malariadrug discovery

11.30 – 12.00 Sheraz Gul, European ScreeningPort

Use of phenotypic assays in academic drug discovery:challenges in identifying the funding, the compounds andthe target

12.00 – 12.30 Snapshots Cisbio, EntomoPharma, Aureliabio, Brooks Life Sciences

12.30 – 2.30 LuNCH/ExHIBITION/POSTER VIEWING Lunchtime workshops

2.30 – 3.00 Justin Bryans, MRCT

Power to the People! Using crowd sourcing toenhance research

3.00 – 3.30 Ed Ainscow, GNF

Academic screening at GNF

3.30 – 4.00 Peter Simpson, AstraZeneca

Innovative Pharma - Academic Partnership models toEnhance Lead Discovery

4.00 – 5.00 POSTER PRESENTATION Charter Foyer

5.00 – 7.00 DRINkS RECEPTION Exhibition Hall

6.30 – 8.00 DRAGONS DEN Exhibition Hall

Assay Development & Screening



9.00 – 9.059.05 – 9.15

Introductions andWelcomeAndrew Leach, GSKTom Heightman, Astex

9.15 – 10.00 Session KeynoteRod Hubbard,Vernalis

Current Perspectives in Fragment Based Drug Discovery

10.00 – 10.30 David Hepworth,Pfizer

Design of a multi-purpose fragment screening library


11.00 – 11.30 Greg Osborne,Heptares

Fragment Based Approaches to GPCRs

11.30 – 12.00 Paul Wyatt,Dundee University

Dundee, Drug Discovery Unit: Using a fragment approachto partially validate novel drug discovery targets

12.00 – 12.30 Snapshots


2.30 – 3.00 Chun-wa Chung,GSK

Pick and mix: optimizing the choice of biophysical andbiochemical for fragment screening

3.00 – 3.30 Rob van Montfort,ICR

Fragment-Based Screening and Structure-Based Design atICR: discovering high quality leads in cancer drug discovery

3.30 – 4.00 Andrew Woodhead,Astex

Discovery and Validation of a Novel Allosteric Binding site onthe HCV Full Length NS3/4a Enzyme




Fragment Discovery for Enzyme & Membrane Targets



9.00 – 9.059.05 – 9.15

Introductions andWelcomeDel Trezise, EssenBioscienceDarren Cawkill, Pfizer

9.15 – 10.00 Session KeynoteMichael Schneider,Imperial University

Pathway Dissection in Cardiac Muscle Cell Death: MAP4K4 asa Therapeutic Target

10.00 – 10.30 James Sidaway,AstraZeneca

Stem cell derived cardiomyocytes for prediction ofdrug-induced structural cardiotoxicity


11.00 – 11.30 Rick Livesey,Cambridge University

Human stem cell models of Alzheimer's disease

11.30 – 12.00 James Bilsland,Neusentis

Generation of hESC-derived sensory neurons for PainDrug Discovery

12.00 – 12.30 Snapshots EssenBioscience, Beckman Coulter, Scottish Biomedical, InSphero


2.30 – 3.00 Davide Danovi,University College London

Live cell image based chemical screens using glioma cells

3.00 – 3.30 Wolfgang Fecke,Siena Biotech

Modulating sphingosine phosphate signaling in recombinant,primary and stem cells – promises and challenges

3.30 – 4.00 Patrick Steigemann,Bayer

3D cell culture for High-Content Drug Screening




Primary Cells & Stem Cells in Discovery



9.00 – 9.059.05 – 9.15

Introductions andWelcomeJason Brown, UbiquigentFrancesco Melandri, Boston BioChem

9.15 – 10.00 Session KeynoteJohn Mayer,Nottingham University

Ubiquitous ubiquitin: From reticulocyte lysates to cellphysiology and disease

10.00 – 10.30 Paul Hales,Millennium

Ubiquitin Proteasome Pathway: Assay development,platform technologies and HTS


11.00 – 11.30 Jennifer Johnston,Elan Pharma

Insight into Parkin E3 ligase activity using small molecules

11.30 – 12.00 Rob Layfield,Nottingham University

Dysfunction of ubiquitin receptors and ubiquitin-mediatedprocesses in human disease

12.00 – 12.30 Snapshots Ubiquigent, Almac


2.30 – 3.00 Xavier Jacq,Mission Therapeutics

DUBs: Therapeutic challenges and opportunities

3.00 – 3.30 Benedikt Kessler,Oxford University

Novel tools for DUB inhibitor specificity profiling incancer cells

3.30 – 4.00 Mike Tatham,Dundee University

The Small Ubiquitin-like Modifiers: Established andemerging roles in diseases




Ubiquitin Cascade Biology & Drug Discovery



Advances in Liquid Handling & Detection Technologies

9.00 – 9.059.05 – 9.15

Introductions andWelcomeKevin Moore, TecanDavid Cronk, BioFocus

9.15 – 10.00 Session KeynoteJohn Bradshaw,Artel

Automating Biology using Robot Scientists

10.00 – 10.30 Bev Isherwood,AstraZeneca

Understanding Error Contribution of Liquid Handling andAnalytical Equipment to Overall Assay Performance


11.00 – 11.30 Ross King,MIB

Application of High-Content Analysis for Phenotypic DrugDiscovery

11.30 – 12.00 Snapshots Tecan


1.45 – 2.15 Dan Thomas,GSK

CompacT SelecT cell culture automation of humanpluripotent stem cells and their progenies

2.15 – 2.45 Melanie Leveridge,GSK

Implementation of Digital Titration to enable highresolution dose-response generation and simplifiedexperimental design

2.45 – 3.15 Yacine Laabi,I-Stem

Simplification of Lead Discovery Using RapidFire™High-Throughput Mass Spectrometry; Addressing theChallenges of Attrition and Cost Reduction

3.15 – 3.45 COFFEE BREAk

3.45 – 5.00 CLOSING kEYNOTE DEBATE:Chris Moxham, LillySteve Rees, AstraZeneca

The Evolving Landscape of Drug DiscoveryLilly Model of Open InnovationCollaborative Models for Lead Discovery

5.00 – 5.15 CLOSE OF CONFERENCE Prize Draw in Charter 1



Compound Collection Management & Enhancement

9.00 – 9.059.05 – 9.15

Introductions andWelcomeMark Wigglesworth, GSKTerry Wood, ELRIG

9.15 – 10.00 Steffen Renner,Novartis

Current thinking in compound collection enhancement

10.00 – 10.30 Andy Merritt,MRCT

MRC-T, an academic perspective on collectionenhancement and/or utilising pharmaceutical collaborationto increase collection diversity


11.00 – 11.30 Ali Tavassoli,Southampton University

Genetic selection of cyclic peptide inhibitors ofprotein-protein interactions

11.30 – 12.00 Snapshots Titian, Pro-Curo, Venomtech, Ziath Ltd


1.45 – 2.15 Chris Lipinski,Massachusetts University

The issue of chemical quality in chemical biology and drugdiscovery: What should one test - a discussion

2.15 – 2.45 Kevin Cross,AstraZeneca,

Logistics of preparing a screening deck: Nanolitre assayready plates and Primary by cherry pick. Current practiceand future dispensing.

2.45 – 3.15 Zoe Blaxill,GSK

Current thinking in ensuring the quality of compoundcollections







Epigentic Drug Discovery

9.00 – 9.059.05 – 9.15

Introductions andWelcomeDavid Wilson, GSKPaul Brennan, Oxford University

9.15 – 10.00 Session KeynoteNessa Carey,Pfizer

The challenges in turning epigenetic hope into clinical utility

10.00 – 10.30 Christopher Schofield,Oxford University

Inhibiting Epigenetic Oxygenases


11.00 – 11.30 Jason Witherington,GSK

Bromodomains: A new class of epigenetic targets ripe forsmall molecule drug discovery

11.30 – 12.00 Snapshots DiscoverX, Cerep


1.45 – 2.15 Giovanna Bergamini,Cellzome

Drug Discovery based on Chemoproteomics of TargetProtein Families

2.15 – 2.45 Margaret Porter-Scott,Epizyme

Reducing histone methyl transferase biology to practice:development of physiologically relevant in vitro assays toidentify hits and successfully develop leads intocandidate molecules

2.45 – 3.15 Doris Hafenbradl,BioFocus

Epigenetic protein targets: Computational approaches andnew assay technologies for efficient hit finding against G9aand LSD1







Biophysics & Label Free Detection Technologies

9.00 – 9.059.05 – 9.15

Introductions andWelcomeAdrian Gill, AstraZenecaLance Laing, ACEA

9.15 – 10.00 Session KeynoteManfred Auer,Edinburgh University

Application of biophysics to drug discovery anddevelopment

10.00 – 10.30 Gerhard Schuetz,Vienna University

Application of single molecule fluorescece trajectories todrug discovery and development


11.00 – 11.30 Karl Andersson,Uppsala University, Sweden

Measuring interaction complexity and time to equilibriumfor biotherapeutics in whole cell assays

11.30 – 12.00 Snapshots Corning


1.45 – 2.15 Barrie Martin,Conformetrix

The application of ligand conformational preferences indrug discovery

2.15 – 2.45 Tim Fagge,GE Healthcare

Analytical Tools for affinity-based label free drug discovery –SPR and Microcalorimetry

2.45 – 3.15 Geoff Holdgate,AstraZeneca

Optical label free and other fragment supporting biophysics





Exhibitors

4titude Ltdwww.4ti.co.uk

Essen BioScience Ltdwww.essenbioscience.com

SiLA Standardization Consortiumwww.sila-standard.org

Agilent Technologies UK Ltdwww.agilent.com/chem

Fluidxwww.2d-tubes.com

STEMCELL Technologieswww.stemcell.com

Almac Group Ltdwww.almacgroup.com

Gilson UKwww.gilsonuk.com

Stevenage Bioscience Catalystwww.stevenagecatalyst.com

AssayMetrics Limitedwww.assaymetrics.com.

Greiner Bio-Onewww.gbo.com

TAP Biosystemswww.tapbiosystems.com

Aurelia Bioscience Ltdwww.aureliabio.com

Hamamatsu Photonics UK Ltdwww.hamamatsu.co.uk

tebu-biowww.tebu-bio.com

Beckman Coulterwww.beckmancoulter.com

Hamilton Robotics Ltdwww.hamiltonrobotics.com

Tecan UK Ltdwww.tecan.com

BigNeat Ltdwww.bigneat.com

HighRes Biosolutions Ltdwww.highresbio.com

Technopath Distribution Ltdwww.techno-path.com

Biocroí Advanced Microplateswww.advancedmicroplates.com

InSphero AGwww.insphero.com

Thermo Scientific (Perbio Science UK Ltd)www.perbio.com

BioDundeewww.biodundee.co.uk

Integrated DNA Technologies BVBAwww.idtdna.com

Titian Software Ltdwww.titian.co.uk

BioScalewww.bioscale.com

IonField Systemswww.ionfieldsystems.com

TTP Labtech Ltdwww.ttplabtech.com

BioTek Instruments Ltdwww.biotek.com

Labcytewww.labcyte.com

Ziath Ltdwww.ziath.com

BMG Labtechwww.bmglabtech.com

Labman Automation Ltdwww.labman.co.uk

Zinsser Analytical GmbHwww.zinsser-analytic.net

Brooks Life Science Systemswww.brooks.com/lifescience

LGC Genomics / KBiosciencewww.lgcgenomics.com Innovation Zone:

Cambridge Biosciencewww.bioscience.co.uk

LGC Standardswww.lgcstandards.com

Biosimswww.biosims.fr

CCS Cell Culture Servicewww.cellcultureservice.com

Life Technologieswww.lifetechnologies.com

Biowakewww.swiftanalytical.com

Cellular Dynamics Internationalwww.cellulardynamics.com

Lonza Cologne GmbHwww.lonza.com

Cyclofluidic Ltdwww.cyclofluidic.co.uk

CEREP SAwww.cerep.com

Matrical Biosciencewww.matrical.com

Cryogattwww.cryogatt.co.uk

Cisbio Bioassayswww.htrf.com

Merck Milliporewww.merckmillipore.com

EntomoPharm ApSwww.entomopharm.com

CM Technologiess Oywww.c-mtechnologies.com

Miltenyi Biotec GmbHwww.miltenyibiotec.com

Flexible Lab Solutions Ltdwww.flexible-lab-solutions.co.uk

Computypewww.computype.com/en-gb

Molecular Deviceswww.MolecularDevices.com

Picodrop Ltdwww.picodrop.com

Contained Air Solutionswww.containedairsolutions.co.uk

Pall Europewww.europe.pall.com

Pro-Curo software Ltdwww.pro-curo.com

Cronus Technologies Ltdwww.cronustechnologies.co.uk

PerkinElmer LAS (UK) Ltdwww.perkinelmer.com

Sirion Biotech GmbHwww.sirion-biotech.com

CyBio Northern Europe Ltdwww.cybio-ag.com

Promega UK Ltdwww.promega.com

Snytheliswww.snythelis.com

Cytoo Cell Architectswww.cytoo.com

ProQinase GmbHwww.proqinase.com

Ubiquigentwww.ubiquigent.com

DiscoveRxwww.discoverx.com

Roche Applied Sciencewww.roche.com

Venomtech limitedwww.venomtech.co.uk

Eppendorf UKwww.eppendorf.co.uk

Scottish Biomedicalwww.scottish-biomedical.com

PicodropTM

μl Spectrophotometry made simplePPPPPμ

Poster Sponsors

MediaSponsors

SessionSponsors

DD 2012 Sponsors

Manchester Central

AZ, Alderley Park

biostorage. ABgene also provides ac

ELRIG 2012/13 Meetings

10th & 11th October 2012Pharmaceutical Flow Cytometry & Imaging

AstraZeneca R&D, Alderley Park

Meetings in 201319th March 2013

Research & InnovationTelford International Centre

19th March 2013Robotic Automation

Mitsubishi Centre, Hatfield

3 & 4th September 2013Drug Discovery 2013

Manchester Central

For more information please contact:Jackie Howard

Email: [email protected] Mob: 07879 050 555

Founding Sponsors

Products &

s

www.strobotics.com.